$32.120
+0.029 (+0.09%)收盤時
IMCR 資訊
IMCR 事件
Immunocore Doses First Patient in Phase 1 Trial of IMC-S118AI
Immunocore announced that the first patient with type 1 diabetes, or T1D, has been dosed in the Phase 1 trial of IMC-S118AI. The Phase 1 dose escalation trial will evaluate the safety, pharmacokinetics and clinical activity of IMC-S118AI in HLA-A02:01-positive type 1 diabetes patients.
Immunocore Achieves Target Patient Enrollment in TEBE-AM Trial
Immunocore announced the achievement of target patient enrollment in the TEBE-AM clinical trial. With target enrollment now achieved, patients enrolled in the trial will continue to be followed for the planned overall survival analysis.
Immunocore Reports Q2 Revenue of $115.93M, Exceeds Expectations
Reports Q2 revenue $115.93M, consensus $110.37M. "The five-year overall survival data for KIMMTRAK underscores the lasting impact of our medicine for patients with metastatic uveal melanoma and reinforces our confidence in the potential of our platform," said Bahija Jallal, CEO of Immunocore. "With enrollment in our Phase 3 TEBE-AM trial nearing target completion and continued progress across our pipeline, we remain focused on our mission: delivering innovative transformative medicines to improve outcomes for patients with serious diseases."
Immunocore Updates Brenetafusp Clinical Trial Results
Immunocore announced updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. The data is presented in a poster at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. In the 66 patients treated with brenetafusp monotherapy, the median overall survival was 14.3 months with a landmark OS rate of 87% at 6 months and 57% at 12 months. The disease control rate was 52%, while the overall response rate was 12%. Multiple measures of clinical benefit were numerically higher for patients treated with the 160 mcg dose - despite worse baseline prognostic factors compared to those treated with 40 mcg. These data support selection of 160 mcg for the ongoing Phase 3 trial evaluating brenetafusp + nivolumab vs. standard nivolumab regimens in first-line advanced melanoma. The safety profile was similar at both doses. Brenetafusp was generally well tolerated, showing a predictable, mechanism-driven safety profile as monotherapy and in combination.
Immunocore Q1 Revenue at $106.68M, Below Consensus
Reports Q1 revenue $106.68M, consensus $107.08M. "We are proud to report another quarter of strong commercial performance, with KIMMTRAK generating $107 million in net revenues in Q1 2026," said Bahija Jallal, CEO of Immunocore. "The five-year overall survival (OS) data from our Phase 3 trial presented at AACR is a landmark moment. It is the longest OS follow-up ever reported in a randomized trial in metastatic uveal melanoma and underscores the long-term benefit KIMMTRAK delivers to patients. In parallel, we are executing with discipline across our pipeline."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。